A Phase 2 interventional study of Pegozafermin and Placebo in Severe Hypertriglyceridemia, sponsored by 89bio, Inc.. Completed at 48 sites in 4 countries. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-25.
Sponsored by 89bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.
Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 54th largest by enrollment of the 145 interventional ones that give a count, is one of 5 that started in 2020, is one of 45 in phase 2, and was the 120th registered.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
Browse Hypertriglyceridemia studies →10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 1 more country
Ages 18+
Marea Therapeutics · Sites in United States
Ages 18–75
The Miriam Hospital · Sites in United States
Ages 18–69
Marea Therapeutics · Sites in United States, Australia, Canada and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 51 · Phase 3 30 · Phase 4 13
First in 1977; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Median enrollment 52 across the 145 interventional studies, 130 across the 3 observational. Of the 124 that completed or were terminated, 57 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 150 have an industry lead sponsor. The 10 most frequent:
89bio, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
89bio, Inc. has 2 studies filed under Hypertriglyceridemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertriglyceridemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681351Phase 3Ionis Pharmaceuticals, Inc.CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | 2027-03 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT05464784MediciNovaMN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | 2026-12-31 |
| NCT07269210Eli Lilly and CompanyA Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | 2027-03 |
| NCT07491172CRISPR Therapeutics AGA Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 150 studies in Hypertriglyceridemia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly [QW] or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pegozafermin 9 mg QW as an SC injection for 8 weeks in the Main Study cohort.
Drug: Pegozafermin
Participants received pegozafermin 18 mg QW as an SC injection for 8 weeks in the Main Study cohort.
Drug: Pegozafermin
Participants received pegozafermin 27 mg QW as an SC injection for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion pegozafermin 27 mg QW groups were pooled together due to low sample size in the expansion cohort.
Drug: Pegozafermin
Participants received pegozafermin 36 mg Q2W as an SC injection for 8 weeks in the Main Study cohort.
Drug: Pegozafermin
Matching placebo was injected at matching frequency per assigned cohort for 8 weeks in the Main Study cohort or Fibrate Expansion cohort. Main Study and Fibrate Expansion placebo groups were pooled together due to low sample size in the expansion cohort.
Drug: Placebo
Subcutaneous injection
Also known as: BIO89-100
Matching placebo
Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)
Time frame: Baseline, Week 8
Number of Participants Who Achieved TG <500 mg/dL at Week 8
Time frame: Week 8
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C)
Least Squares Means were calculated using mixed-model repeated measures (MMRM).
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG
Time frame: Baseline, Week 8
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight
Least Squares Mean was calculated using MMRM.
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)
Least Squares Mean was calculated using analysis of covariance (ANCOVA).
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)
Time frame: Baseline, Week 8
Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
Least Squares Mean was calculated using MMRM.
Time frame: Baseline, Week 8
| Milestone | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo |
|---|---|---|---|---|---|
| Started | 16 | 17 | 16 | 16 | 15 |
| Safety analysis set | 12 | 21 | 15 | 16 | 15 |
| Full analysis set (fas) | 16 | 17 | 13 | 16 | 14 |
| Completed | 15 | 16 | 10 | 15 | 14 |
| Not completed | 1 | 1 | 6 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 4 | 0 | 0 |
| Withdrew: Investigator decision | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Covid-19-related dose interruption | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Randomized in error not treated | 0 | 0 | 1 | 0 | 0 |
| Milestone | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo |
|---|---|---|---|---|---|
| Started | 0 | 0 | 3 | 0 | 3 |
| Received at least 1 dose of study drug | 0 | 0 | 3 | 0 | 3 |
| Full analysis set | 0 | 0 | 3 | 0 | 3 |
| Completed | 0 | 0 | 3 | 0 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 1 |
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Serum Triglyceride (TG) | -57.33 (-69.07 to -32.31) | -11.85 (-23.22 to 7.88) |
| Participants | Pegozafermin | Placebo |
|---|---|---|
| Number of Participants Who Achieved TG <500 mg/dL at Week 8 | 51 | 5 |
Least Squares Means were calculated using mixed-model repeated measures (MMRM).
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| Non-HDL-C | -18.29 ± 2.943 | -0.57 ± 5.586 |
| ApoB | -10.51 ± 2.238 | 1.07 ± 4.309 |
| LDL-C | 10.44 ± 4.654 | 8.72 ± 9.018 |
| HDL-C | 24.65 ± 3.752 | 9.67 ± 7.045 |
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| VLDL-C | -47.96 (-63.14 to -16.67) | -0.41 (-30.38 to 10.98) |
| VLDL-TG | -58.50 (-72.53 to -32.80) | -0.85 (-27.72 to 14.25) |
Least Squares Mean was calculated using MMRM.
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| Fasting Plasma Glucose | -3.90 ± 2.681 | -2.67 ± 5.230 |
| Adiponectin | 69.53 ± 7.383 | 5.70 ± 14.556 |
| Body Weight | -0.15 ± 0.339 | -0.14 ± 0.654 |
Least Squares Mean was calculated using analysis of covariance (ANCOVA).
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF) | -42.18 ± 6.207 | -8.26 ± 11.214 |
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP) | -21.43 (-43.30 to 42.37) | -1.10 (-50.41 to 18.84) |
Least Squares Mean was calculated using MMRM.
| percent change from Baseline | Pegozafermin | Placebo |
|---|---|---|
| ALT | -4.28 ± 4.549 | 0.43 ± 8.881 |
| AST | -11.50 ± 3.341 | 0.51 ± 6.597 |
Collected over Day 1 (after dosing) up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegozafermin 9 mg QW | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Pegozafermin 18 mg QW | 0/21 (0%) | 0/21 (0%) | 13/21 (61.9%) |
| Pegozafermin 27 mg QW | 0/18 (0%) | 1/18 (5.6%) | 13/18 (72.2%) |
| Pegozafermin 36 mg Q2W | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Placebo | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Event | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo |
|---|---|---|---|---|---|
| HypertensionVascular disorders | 0/12 | 0/21 | 1/18 | 0/16 | 0/18 |
| Event | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/12 | 1/21 | 5/18 | 2/16 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 1/21 | 4/18 | 0/16 | 1/18 |
| COVID-19Infections and infestations | 0/12 | 3/21 | 0/18 | 1/16 | 3/18 |
| Injection site reactionGeneral disorders | 1/12 | 2/21 | 1/18 | 2/16 | 0/18 |
| Injection site erythemaGeneral disorders | 0/12 | 1/21 | 2/18 | 1/16 | 0/18 |
| Abdominal painGastrointestinal disorders | 0/12 | 0/21 | 2/18 | 1/16 | 0/18 |
| FatigueGeneral disorders | 0/12 | 0/21 | 1/18 | 0/16 | 2/18 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 0/21 | 2/18 | 0/16 | 0/18 |
| HeadacheNervous system disorders | 0/12 | 0/21 | 0/18 | 0/16 | 2/18 |
| Injection site pruritusGeneral disorders | 1/12 | 2/21 | 1/18 | 0/16 | 0/18 |
Safety Analysis Set: All participants who received at least 1 dose of study drug. Participants are summarized by treatment received. As per SAP, since a low number of participants enrolled in the fibrate cohort, participants randomized to pegozafermin 27 mg QW fibrate cohort were combined with the pegozafermin 27 mg QW main cohort, forming a pooled pegozafermin 27 mg QW group for analyses. Similarly, the placebo participants in the fibrate cohort were combined with the main placebo group.
| Age, Continuous(years) | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 52.8 ± 14.12 | 51.3 ± 10.81 | 53.9 ± 7.18 | 53.1 ± 12.36 | 57.5 ± 10.30 | 53.7 ± 10.86 |
| Sex: Female, Male(Participants) | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 4 | 5 | 2 | 6 | 21 |
| Male | 8 | 17 | 13 | 14 | 12 | 64 |
| Ethnicity (NIH/OMB)(Participants) | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 4 | 5 | 3 | 17 |
| Not Hispanic or Latino | 9 | 19 | 14 | 11 | 15 | 68 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo | Total |
|---|---|---|---|---|---|---|
| Race — Black | 1 | 0 | 0 | 0 | 1 | 2 |
| Race — White | 11 | 21 | 18 | 14 | 17 | 81 |
| Race — Not Reported | 0 | 0 | 0 | 1 | 0 | 1 |
| Race — Unknown | 0 | 0 | 0 | 1 | 0 | 1 |
| Triglyceride (TG) Level(Participants) | Pegozafermin 9 mg QW | Pegozafermin 18 mg QW | Pegozafermin 27 mg QW | Pegozafermin 36 mg Q2W | Placebo | Total |
|---|---|---|---|---|---|---|
| <750 mg/dL | 9 | 14 | 12 | 9 | 13 | 57 |
| ≥750 mg/dL | 3 | 7 | 6 | 7 | 5 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in May 2022, 20 months.
Results were first posted in Jul 2024, 2 years 2 months after primary completion.
Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegozafermin
89bio, Inc.